Host-Microbe Interactions in the Neonatal Intestine: Role of Human Milk Oligosaccharides

Sharon M. Donovan, Mei Wang, Min Li, Iddo Friedberg, Scott L. Schwartz, and Robert S. Chapkin

Abstract

The infant intestinal microbiota is shaped by genetics and environment, including the route of delivery and early dietary intake. Data from germ-free rodents and piglets support a critical role for the microbiota in regulating gastrointestinal and immune development. Human milk oligosaccharides (HMO) both directly and indirectly influence intestinal development by regulating cell proliferation, acting as prebiotics for beneficial bacteria and modulating immune development. We have shown that the gut microbiota, the microbial metatranscriptome, and metabolome differ between porcine milk-fed and formula-fed (FF) piglets. Our goal is to define how early nutrition, specifically HMO, shapes host-microbe interactions in breast-fed (BF) and FF human infants. We an established noninvasive method that uses stool samples containing intact sloughed epithelial cells to quantify intestinal gene expression profiles in human infants. We hypothesized that a systems biology approach, combining i) HMO composition of the mother’s milk with the infant’s gut gene expression and fecal bacterial composition, ii) gene expression, and iii) short-chain fatty acid profiles would identify important mechanistic pathways affecting intestinal development of BF and FF infants in the first few months of life. HMO composition was analyzed by HPLC Chip/time-of-flight MS and 3 HMO clusters were identified using principle component analysis. Initial findings indicated that both host epithelial cell mRNA expression and the microbial phylogenetic profiles provided strong feature sets that distinctly classified the BF and FF infants. Ongoing analyses are designed to integrate the host transcriptome, bacterial phylogenetic profiles, and functional metagenomic data using multivariate statistical analyses.

Introduction

A mother’s microbiota and breast milk and the infant’s microbiome represent an intricately linked triad that is central to an infant’s intestinal and immune development (1). Almost immediately after birth (2), the infant acquires an intestinal microbiota that is seeded by maternally derived microbes (3), nurtured by components in human milk (HM) (4), and shaped by the infant’s genetic background (5). Key to establishing the microbiota are the infant’s route of delivery (3), which dictates the degree of exposure to the mother’s vaginal and fecal microbes, and early nutrition, which determines the infant’s exposure to dietary oligosaccharides (2,5,6). Nutrients and bioactive components in HM directly influence the development of the infant’s immune system (7,8), actively protect the infant from pathogenic infection (7,9), and facilitate the establishment of the microbiota (5,6), the latter of which is required to activate the mucosal immune system (10). As such, HM provides a means whereby a mother can nourish and protect her infant by promoting immune development and decreasing the incidence and/or severity of infectious diseases (11–13).

1 Department of Food Science and Human Nutrition, University of Illinois, Urbana, IL; Departments of 2Microbiology and 3Computer Science and Software Engineering, Miami University, Oxford, OH; 4Program in Integrative Nutrition and Complex Diseases, Center for Environmental and Rural Health and 5Department of Statistics, Texas A&M University, College Station, TX

Abbreviations used: BF, breast-fed; CoD, coefficient of determination analysis; CM, conventional microbiota; EPS51, endothelial PAS domain–containing protein 1; FF, formula-fed; HM, human milk; HMO, human milk oligosaccharides; NEC, necrotizing enterocolitis; PM, porcine milk; PMO, porcine milk oligosaccharides.

It has long been appreciated that the composition of the microbiota differs between breast-fed (BF) and formula-fed (FF) infants with a higher proportion of bifidobacteria species in the BF infant (14). In the past decade, nucleic acid–based approaches have been applied to define the succession of the neonatal microbiota (2–4,15,16). These culture-independent approaches have uncovered a greater diversity of microbes in the neonatal intestine than had been previously appreciated, while confirming that bifidobacteria constitute 60% to 91% and ~50% of the fecal bacterial community of BF and FF infants, respectively (4,15,16). This preponderance of bifidobacteria led to the speculation of the presence of bifidus factor in HM, which was initially identified as N-acetylglycosamine-containing oligosaccharides (17). The application of modern analytical techniques over the past decade has revealed that HM contains a rich diversity of oligosaccharides (HMO) (18). Furthermore, the HMO concentration exceeds that of any other species’ milk by 10- to 100-fold (19,20), suggesting a potentially unique role of HMO in human infant development. Indeed, HMO exert broad-spectrum benefit for the infant, including acting as a component of the immunity of HM by modulating the infant’s immune development, blocking the attachment of pathogens, and serving as prebiotics to promote colonization by a healthy gut microbiota (9,21,22), including bifidobacteria (23).

The neonatal gastrointestinal tract undergoes pronounced structural and functional changes in response to feeding (7). Although HM is generally considered to be trophic for the gut, proper gut development must balance proliferation, differentiation, and apoptosis (7). Kuntz et al. (24,25) reported that HMO are strong inhibitors of proliferation and inducers of differentiation in intestinal cells in vitro by altering cell cycle dynamics via corresponding regulator genes and mitogen-activated protein kinase signaling (25). Thus, HMO have the potential to modulate neonatal gut growth through direct interactions with epithelial cells as well as indirectly, by modulating the microbiota and their fermentation products, such as butyrate, which may be trophic for gut epithelial cells (26).

Our long-term goal is to elucidate host-microbe interactions within the neonatal intestine in which the impact of diet on microbial colonization, bacterial metabolites, and gene expression and host neonatal intestinal gene expression are being measured concurrently. In this review, the current evidence linking HMO to host-microbe interactions in the infant gut is discussed as well as initial findings from our endeavor to systematically integrate genomic data from both the infant (host mucosa) and gut microbiota to define host gene–diet interactions within the context of the structure and operations of gut microbial communities.

**Current status of knowledge**

**What components in the diet affect the intestinal microbiota?**

The composition of the intestinal microbiota is highly variable in early infancy and largely stabilizes by the end of the first year of life (27). In BF infants, *Bifidobacterium* spp. become the predominant group of organisms by ~3 mo of age (4), whereas FF infants develop a microbial community composed of some bifidobacteria, but also *Bacteroides, Clostridia, Enterococcus*, and *Staphylococcus* (14). HM promotes the growth of *Bifidobacterium* spp. This bifidogenic activity is likely attributed to both the protein and carbohydrate components in HM. For example, growth of bifidobacteria is promoted by lactoferrin both in vitro (28) and in vivo (29). In addition, peptides produced by in vitro proteolytic digestion of lactoferrin and secretory component are bifidogenic (30). However, most recent studies have focused on HMO as the primary bifidogenic components of HM (22). Indeed, findings from the laboratories of David Miller, Carlito Lebrilla, and colleagues at the University of California at Davis provide evidence that *Bifidobacterium longum* subsp. *infantis* is uniquely adapted for the BF infant (6,22). Parallel glycoprofiling of HMO established that *B. longum* subsp. *infantis* ATCC15697 efficiently consumes several predominant small-mass HMO isomers (31). Genome sequencing of *Bifidobacterium* confirmed that *B. infantis* strains share several large clusters containing all of the genes necessary for transport and enzymatic degradation of HMO (32). Thus, the microbiota of the BF infant contains bacteria that are specialized to metabolize HMO. The implications of these findings is described in greater detail in other articles in this supplement (33,34).

**What bacteria and their genes are involved in the host-microbe interaction?**

Mammals exist in a mutualistic relationship with their microbiota in which the host provides nutrients and a stable environment for the microbiota, which in turn stimulates development and metabolic activity of the host (35–37). There is abundant evidence from mice and humans documenting that microbes adapt to their environmental niche and concomitantly influence host phenotype (38–42). For example, it was recently demonstrated that crosstalk between lymphocytes, microbiota, and the intestinal epithelium governs immunity versus metabolism in the gut (43). However, precisely how diet shapes the structure and function of gut microbial communities in newborn infants is poorly understood. Given that the microbiota and dietary composition differ between BF and FF infants, it is reasonable to hypothesize that the microbial metatranscriptome would also differ. To address this hypothesis, pyrosequencing-based whole-transcriptome shotgun sequencing was used to evaluate community-wide gut microbial gene expression in the cecal contents of 21-day-old piglets fed either with porcine milk (PM) or formula (44). PM contains both acidic (sialylated) and neutral oligosaccharides (PMO) (45). Using MS, 29 distinct PMO structures were detected in PM, of which most were sialylated (e.g., sialyllactose). Six fucosylated PMO were also detected (45). The presence of oligosaccharides was not measured in the PM replacer formula fed to the piglets in this study; however, most cow milk–based formulas contain only very low concentrations of sialyllactose (46). Microbial DNA and RNA were
harvested, and both cDNA libraries and 16S recombinant DNA amplicons were sequenced. Communities were similar at the phylum level, but were dissimilar at the genus level; *Prevotella* was the dominant genus in PM samples and *Bacteroides* was most abundant in formula samples. The functional annotations of screened cDNA sequences were assigned by the metagenomics RAST annotation pipeline and based on best BLASTX hits to the NCBI COG database. Patterns of gene expression were very similar in PM-fed and FF animals; all samples were enriched with transcripts encoding proteins involved in carbohydrate and protein metabolism, stress response, binding to host epithelium and lipopolysaccharide metabolism. However, expression of genes involved in amino acid metabolism (e.g., arginine metabolism) and oxidative stress were enriched in PM-fed versus FF piglets (44). This finding may have clinical relevance because low serum arginine, a precursor of nitric oxide production, confers an increased risk of necrotizing enterocolitis (NEC) (47), and the incidence of NEC is lower in preterm infants fed HM (48). To further define the impact of diet on intraluminal metabolites, cecal contents of the same piglets were analyzed by GC/MS (49). Sugars, amino sugars, fatty acids, especially unsaturated fatty acids, and sterols were identified as being among the most important metabolites for distinguishing between PM-fed and FF groups. Joint analysis of microbiota and metabolomics pinpointed specific sets of metabolites associated with the dominant bacterial taxa. Therefore, we concluded that diet composition has a significant role in defining the microbiota and metabolic products in the developing gut. Interestingly, recent studies indicate that our piglet data are translatable to human infant stool samples (49,50). In summary, tandem analysis of intestinal microbial, transcriptomic, and metabolic profiles is a powerful tool for delineating the role of diet in health and disease and, ultimately, designing specific strategies to alter microbial behavior to improve clinical outcome.

**Which host genes are involved in the host-microbe interaction and respond to bacterial signals?**

Gnotobiotic animals provide a unique model in which to dissect the influence of a single bacteria or a complex microbiota on the host (51). Studies in germ-free animals have confirmed that the commensal microbiota is required for normal intestinal epithelial cell proliferation and migration and maintenance of villus morphology (35), immune development (36), energy balance, regulation of blood pressure, and risk of disease (37–39). A now common experimental approach is to colonize germ-free animals with a complex microbiota or to monoassociate with a single microbe (36–41,51). Colonization of gnotobiotic piglets with a conventional microbiota (CM) induced the expression of genes contributing to intestinal epithelial cell turnover, mucus biosynthesis, and priming of the immune system (52,53). Gut growth (53), digestive enzyme mRNA expression activities (54), and chemokines and their receptors (55) were differentially affected when gnotobiotic piglets were colonized with CM versus gram-negative *Escherichia coli* or gram-positive *Lactobacillus fermentum*. The CM and *E. coli*, but not *L. fermentum*, increased overall intestinal cell turnover in the piglets by stimulating increased apoptosis through the expression of Fas ligand and TNF-α and by increasing cell proliferation (53). Similarly, the ratio of enzyme mRNA expression to activity differed between CM and germ-free piglets and piglets colonized by a single microbe (54). The authors hypothesized that enterocyte upregulation of aminopeptidase N expression occurred as either a direct response to microbial colonization or as a feedback mechanism in response to reduced enzyme activity through microbial degradation. This mechanism may play a role in ensuring effective competition of the host with the intestinal microbiota for available nutrients (54).

Thus, data obtained by our laboratory (44,49) and others (52–55) using the piglet model have provided insight into host-microbe interactions in the neonatal gut. Stool samples are easy to obtain from infants, but it is extremely difficult to obtain intestinal biopsy samples from healthy infants to measure mucosal gene expression. To overcome this limitation, we established a noninvasive molecular methodology that uses stool samples containing intact sloughed epithelial cells to study intestinal gene expression in human infants (56). A total 1214 probe sets were differentially expressed in epithelial cells of BF and FF infants, which were compared...
with a database of 529 genes known to be involved in intestinal biology. Of these, 146 were differentially expressed in BF and FF infants. These genes were functionally analyzed using Metacore (GeneGo). Differentially expressed genes were fit into the following gene networks: signal transduction, cytoskeleton remodeling, cell migration, cell adhesion, barrier function, immune response, inflammation, and histamine (Figure 1). Linear discriminant analysis was used to identify the single genes and the 2- to 3-gene combinations that best distinguished BF from FF infants. In addition, putative "master" regulatory genes were identified using coefficient of determination (CoD) analysis. The best-performing gene using linear discriminant analysis was endothelial PAS domain-containing protein 1 (EPAS1), which was significantly (3-fold) upregulated in BF compared with FF infants. The EPAS1 protein is a basic helix-loop-helix PAS transcription factor that is activated by hypoxia leading to subsequent induction of vascular development (57). This is noteworthy because hypoxia-triggered angiogenesis may affect predisposition to proinflammatory states, including NEC (58). Although the role of EPAS1 in the developing human intestine has not been studied, CoD analyses confirmed its importance as a master regulatory gene that appears to drive the expression of other genes; thus, it is worthy of further investigation. The power of the CoD approach lies in its ability to find unexpected links between processes not previously known to be coordinated by signaling pathways. In summary, we showed for the first time that 2- and 3-gene combinations provide classifiers with potential to noninvasively identify discriminative signatures for the development of molecular markers to explore nutritional effects on maturation of intestinal function (56).

We recently expanded this data set to include the HMO content of the mother's milk and the infant's fecal short-chain fatty acid content, microbial composition, and the bacterial microbiome by 454 pyrosequencing of DNA libraries. HMO were profiled in the laboratory of Dr. Carlito Lebrilla (University of California, Davis) using HLPC Chip/time-of-flight MS and were identified using an annotated HMO library (59,60). HMO profiles were analyzed using principal components analysis of human milk oligosaccharides (HMO) profiles. The HMO profiles in samples collected at 3-mo of lactation were determined using HLPC chip/time-of-flight MS and identified compared with annotated HMO libraries (57,58). HMO profiles were compared using principal components analysis, which identified 3 clusters that primarily separated based on the content of 2 predominant HMO, 2'-fucosyllactose and lacto-N-tetraose. The 2'-fucosyllactose content increases and the lacto-N-tetraose content decreases from left to right. We conclude that genetic variation in secretor status (61) exists in the mothers enrolled in our study, which will facilitate establishing associations between milk HMO and infant microbiota.

Figure 2 Principal components analysis of human milk oligosaccharides (HMO) profiles. The HMO profiles in samples collected at 3-mo of lactation were determined using HLPC chip/time-of-flight MS and identified compared with annotated HMO libraries (57,58). HMO profiles were compared using principal components analysis, which identified 3 clusters that primarily separated based on the content of 2 predominant HMO, 2'-fucosyllactose and lacto-N-tetraose. The 2'-fucosyllactose content increases and the lacto-N-tetraose content decreases from left to right. We conclude that genetic variation in secretor status (61) exists in the mothers enrolled in our study, which will facilitate establishing associations between milk HMO and infant microbiota.

**Figure 2** Principal components analysis of human milk oligosaccharides (HMO) profiles. The HMO profiles in samples collected at 3-mo of lactation were determined using HLPC chip/time-of-flight MS and identified compared with annotated HMO libraries (57,58). HMO profiles were compared using principal components analysis, which identified 3 clusters that primarily separated based on the content of 2 predominant HMO, 2'-fucosyllactose and lacto-N-tetraose. The 2'-fucosyllactose content increases and the lacto-N-tetraose content decreases from left to right. We conclude that genetic variation in secretor status (61) exists in the mothers enrolled in our study, which will facilitate establishing associations between milk HMO and infant microbiota.

**Figure 3** Bacterial phyla in stool of 3-mo-old breast- and formula-fed infants. Genomic DNA was extracted from stool and the bacterial 16S recombinant RNA gene V1 to V3 regions were amplified with primers 27F RegS and 534R. Primer 27F RegS contained sequencing primer and barcode (MID). PCR products were purified and quantified, and amplicons were mixed in equimolar concentration and sequenced using 454 Life Sciences Genome Sequencer FLX with GS FLX Titanium series reagents at the Keck Center for Comparative and Functional Genomics at the University of Illinois, Urbana. 16S recombinant RNA gene sequences were processed and analyzed using the Mothur program (63). Sequences were classified to phylum by comparing with RDP training set. Breast-fed infants had a higher percentage of Bacteroidetes and lower Firmicutes and Verrucomicrobia compared with formula-fed infants.
Conclusions and future directions
Clinical and epidemiological data support differences in the development, microbiota, and incidence of disease between BF and FF infants (1,13). These data are consistent with a growing body of data indicating that perinatal diet orchestrates mucosal homeostasis (62). Given the abundance and diversity of HMO and their broad physiological actions and their absence in infant formula (6,22), it is tempting to speculate that HMO are in part responsible for these differences between BF and FF infants. Systematic evaluation of the impact of HMO on infant development has been limited by the lack of sufficient quantities of pure HMO to conduct animal or human feeding studies. However, in the near future, this limitation will be overcome through improved synthetic approaches, opening avenues of investigation into the biology of HMO. Additionally, the availability of noninvasive methods of assessing outcomes in human infants (56) and high throughput methods for measuring HMO and infant microbiome will facilitate our understanding of the role of HMO in host-microbe interactions in the developing infant.

Acknowledgments
The authors thank Shuai Wu and Dr. Carlito Lebrilla at the University of California, Davis for performing the HMO analysis. All authors have read and approved the final manuscript.

Literature Cited
6. Zivkovic AM, German JB, Lebrilla CB, Mills DA. Human milk glyco-
7. Donovan SM. Role of human milk components in gastrointestinal develop-
16. Boesten R, Schuren F, Ben Amore K, Haarman M, Know J, deVos WM. Bifi-
dobacterium population analysis in the infant gut by direct mapping of genomic hybridization patterns: potential for monitoring temporal develop-
21. Bode L. Recent advances on structure, metabolism, and function of hu-
22. Sela DA, Mills DA. Nursing our microbiota: molecular linkages be-
26. Shen Q, Tuohy KM, Gibson GR, Ward RE. In vitro measurement of the impact of human milk oligosaccharides on the faecal microbiota of weaned formula-fed infants compared to a mixture of probiotic fruc-
28. Rahman MM, Kim WS, Ito T, Kumura H, Shimazaki K. Growth pro-